Nordic Nanovector ASA (NANO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Nordic Nanovector ASA (NANO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8240
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ノルウェー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Nordic Nanovector ASA (Nordic Nanovector), formerly Nordic Nanovector AS is a developer and commercializer of antibody radionuclide conjugates for the treatment of haematological cancers. The company’s lead product candidate includes Betalutin, an antibody radionuclide conjugate developed for the treatment of non-Hodgkin Lymphoma, a life-threatening blood cancer. Its Betalutin consists of tumour-specific antibody HH1, which targets CD37 antigen on the surface of NHL cells. Nordic Nanovector develops products for the treatment of multiple cancer indications by utilizing innovative therapy programmes and patented technologies. The company evaluates chimeric anti-CD37 antibodies with different payloads for the treatment of both types of leukaemia. It operates in Norway, Switzerland and the UK. Nordic Nanovector is headquartered in Oslo, Norway.

Nordic Nanovector ASA (NANO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nordic Nanovector ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Nordic Nanovector Raises USD8.34 Million In A Financing Round 11
Nordic Nanovector Raises US$10 Million In Series A Financing 12
Nordic Nanovector Raises US$2.4 Million In Venture Financing 13
Partnerships 14
Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 14
Nordic Nanovector Enters into Partnership with LegoChem Biosciences 15
Nordic Nanovector Enters into Agreement with Areva Med 16
Nordic Nanovector Enters into R&D Agreement with Paul Scherrer Institute 17
Nordic Nanovector Enters into Co-Development Agreement with Affibody 18
Equity Offering 19
Nordic Nanovector Raises USD1.2 Million in Rights Offering of Shares 19
Nordic Nanovector Raises USD59 Million in Private Placement of Shares 20
Nordic Nanovector Completes IPO 21
Nordic Nanovector Raises USD7.7 Million in Rights Offering of Shares 23
Nordic Nanovector Raises USD41.7 Million in Private Placement of Shares 24
Nordic Nanovector ASA – Key Competitors 25
Nordic Nanovector ASA – Key Employees 26
Nordic Nanovector ASA – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 22, 2018: Nordic Nanovector: results for the second quarter and first half 2018 28
May 30, 2018: Nordic Nanovector – Results for the First Quarter 2018 31
Feb 27, 2018: Nordic Nanovector- Results for the Fourth Quarter and Full Year 2017: Solid Performance Through 2017, Moving Forward With Pivotal Trial 32
Nov 22, 2017: Nordic Nanovector – Results for the Third Quarter 2017 34
Aug 23, 2017: Nordic Nanovector – Results for Second Quarter and First Half Year 2017 36
May 24, 2017: Nordic Nanovector: Results for First Quarter 2017 38
Feb 28, 2017: Nordic Nanovector: Results for Fourth Quarter and Full Year 2016 39
Corporate Communications 40
Jun 01, 2018: Nordic Nanovector Strengthens Management Team With Appointment of Maureen Deehan, PhD, as Head of Corporate Development and Strategy 40
May 30, 2018: Nordic Nanovector Names Rainer Boehm As Board Director 41
Apr 20, 2018: Nordic Nanovector Appoints Tone Kvale As Interim Chief Executive Officer 42
Apr 04, 2018: Nordic Nanovector announces that Luigi Costa will step down as Chief Executive Officer 43
Product News 44
01/04/2017: Nordic Nanovector to Present at Biotech Showcase 2017 44
Clinical Trials 45
Mar 15, 2018: Nordic Nanovector to Present Preclinical Data Highlighting the Anti-tumour Effect of Humalutin in Three Lymphoma Models at AACR 2018 45
Mar 17, 2017: Nordic Nanovector announces first patient dosed in Phase 1 study of Betalutin in diffuse large B-cell lymphoma, an aggressive form of NHL 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nordic Nanovector ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nordic Nanovector ASA, Deals By Therapy Area, 2012 to YTD 2018 9
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nordic Nanovector Raises USD8.34 Million In A Financing Round 11
Nordic Nanovector Raises US$10 Million In Series A Financing 12
Nordic Nanovector Raises US$2.4 Million In Venture Financing 13
Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 14
Nordic Nanovector Enters into Partnership with LegoChem Biosciences 15
Nordic Nanovector Enters into Agreement with Areva Med 16
Nordic Nanovector Enters into R&D Agreement with Paul Scherrer Institute 17
Nordic Nanovector Enters into Co-Development Agreement with Affibody 18
Nordic Nanovector Raises USD1.2 Million in Rights Offering of Shares 19
Nordic Nanovector Raises USD59 Million in Private Placement of Shares 20
Nordic Nanovector Completes IPO 21
Nordic Nanovector Raises USD7.7 Million in Rights Offering of Shares 23
Nordic Nanovector Raises USD41.7 Million in Private Placement of Shares 24
Nordic Nanovector ASA, Key Competitors 25
Nordic Nanovector ASA, Key Employees 26
Nordic Nanovector ASA, Subsidiaries 27

List of Figures
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Nordic Nanovector ASA (NANO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • EyePoint Pharmaceuticals Inc (PSDV):製薬・医療:M&Aディール及び事業提携情報
    Summary EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert and durasert, among others. Its durasert …
  • salesforce.com, inc.:戦略・SWOT・企業財務分析
    salesforce.com, inc. - Strategy, SWOT and Corporate Finance Report Summary salesforce.com, inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Fera Pharmaceuticals LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Fera Pharmaceuticals LLC (Fera) is a pharmaceutical company that develops, markets and commercializes ointments and medicines. The company offers neptazane, bacitracin ophthalmic ointment USP, neo-polycin HC, and others. It offers various treatment options for patient and healthcare communit …
  • Futuren (FTRN):企業の財務・戦略的SWOT分析
    Futuren (FTRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Inform Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Inform Diagnostics Inc(Inform Diagnostics) formerly known as Miraca Life Sciences, a subsidiary of Miraca Holdings Inc, is an anatomic pathology laboratory that offers diagnostic services. The laboratory provides services in the areas of breast health, dermatology, gastroenterology, hematolo …
  • Mapfre SA (MAP):企業の財務・戦略的SWOT分析
    Mapfre SA (MAP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • RTI Surgical Inc (RTIX):企業の財務・戦略的SWOT分析
    Summary RTI Surgical Inc (RTI), formerly RTI Biologics Inc is a surgical implant company that offers biologic, metal and synthetic implants. The company’s products include spine implants, surgical specialties, sports medicine implants, cardiothoracic and orthobiologics. It offers spine implants such …
  • Ricoh Leasing Company, Ltd.:企業の戦略・SWOT・財務情報
    Ricoh Leasing Company, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Ricoh Leasing Company, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Magellan Midstream Partners LP (MMP):企業の財務・戦略的SWOT分析
    Magellan Midstream Partners LP (MMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Companhia de Saneamento Basico do Estado de Sao Paulo (SBSP3):企業の財務・戦略的SWOT分析
    Summary Companhia de Saneamento Basico do Estado de Sao Paulo (SABESP) is an environmental consulting company that is responsible for supplying water and collecting and treating sewage in municipalities of Sao Paulo state. The company provides water and sewage services in another four municipalities …
  • Hero MotoCorp Ltd:戦略・SWOT・企業財務分析
    Hero MotoCorp Ltd - Strategy, SWOT and Corporate Finance Report Summary Hero MotoCorp Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • BW Group Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary BW Group Ltd (BW Group) formerly Bergesen Worldwide Limited, is an oil and gas company which provides maritime services. The company offers oil and gas shipping and others related services. It offers environmental technologies, floating gas infrastructure, and deepwater production services. …
  • Solstad Offshore ASA (SOFF):企業の財務・戦略的SWOT分析
    Summary Solstad Offshore ASA (Solstad) formerly Solstad Farstad ASA is an oil and gas company that provides vessel operation solutions. The company offers carbon footprint, climate neutral network, offshore shipping, green operations, and rainforest protection, documentation programs. It operates th …
  • ACB Securities Co Ltd:企業の戦略的SWOT分析
    ACB Securities Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • OpGen Inc (OPGN)-医療機器分野:企業M&A・提携分析
    Summary OpGen Inc (OpGen) is a molecular diagnostics company that harnesses genomic analysis and bioinformatics to prevent the threat of antibiotic resistance and multi drug resistant organisms (MDROs). The company’s clinical laboratory services include high resolution microbial sequence analysis, s …
  • Bosideng International Holdings Limited
    Bosideng International Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Bosideng International Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Reliance Capital Ltd:企業の戦略・SWOT・財務情報
    Reliance Capital Ltd - Strategy, SWOT and Corporate Finance Report Summary Reliance Capital Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Ossur hf (OSSR)-医療機器分野:企業M&A・提携分析
    Summary Ossur hf. (Ossur) is an orthopedic devices company. It develops, manufactures and sells prosthetics, and bracing and support products. The company’s key areas of expertise include silicone, carbon composites, mechatronics and textiles. Ossur offers ankle and foot supports, knee braces, neck …
  • Pacific Textiles Holdings Ltd (1382):企業の財務・戦略的SWOT分析
    Pacific Textiles Holdings Ltd (1382) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Starkey Hearing Technologies Inc:企業の戦略的SWOT分析
    Starkey Hearing Technologies Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆